Rapport Therapeutics

Rapport Therapeutics
Name	Rapport Therapeutics
Industry	Biotechnology
Founded	2022
Founder	David Bredt
Hq location	Boston, Massachusetts
Key people	Abraham Ceesay (CEO), David Bredt (Chief Scientific Officer)
Products	Small molecule therapeutics
Website	rapportrx.com

Rapport Therapeutics. It is a clinical-stage biotechnology company focused on developing precision medicines for neurological and psychiatric disorders by targeting receptor-associated proteins. Founded in 2022 by renowned neuroscientist David Bredt, the company leverages a novel platform to identify small molecule drugs that modulate specific protein complexes within the central nervous system. Rapport's approach aims to create therapies with improved efficacy and reduced side effects compared to traditional broad-spectrum neurological drugs, with an initial focus on conditions like focal epilepsy and neuropathic pain.

Company overview

Rapport Therapeutics operates as a private entity headquartered in the Boston metropolitan area, a major hub for the life sciences industry. The company's mission centers on translating foundational discoveries in synaptic biology into targeted therapeutics for patients with debilitating brain disorders. Its scientific strategy is built upon the concept of targeting auxiliary proteins that regulate the function of primary ion channels and G protein-coupled receptors, a departure from conventional drug discovery efforts aimed at the receptors themselves. This precision approach is designed to intervene in disease pathways with greater selectivity, potentially avoiding the off-target effects that have plagued many central nervous system drug development programs. The firm has attracted significant venture capital funding from top-tier firms like Third Rock Ventures and Johnson & Johnson Innovation.

History and development

The company was founded in 2022 by David Bredt, a prominent neuroscientist previously serving as Head of Neuroscience at Johnson & Johnson and known for his co-discovery of neuronal nitric oxide synthase. The formation of the company was catalyzed by groundbreaking research into the organization of postsynaptic density proteins and the functional specialization of scaffolding proteins like PSD-95. Rapport emerged from stealth mode in 2023 with a substantial Series A financing round co-led by Third Rock Ventures and Johnson & Johnson Innovation, securing $100 million to advance its platform and pipeline. This rapid establishment and funding underscore the high level of confidence from the biotechnology investment community in both the foundational science and the experienced leadership team assembled to execute the company's vision.

Technology and platform

Rapport's core technology platform is based on the identification and pharmacological targeting of receptor-associated proteins, specifically those within the membrane-associated guanylate kinase family. These proteins, such as PSD-95, act as critical scaffolding proteins that organize neurotransmitter receptors and ion channels at the synapse, influencing signal transduction and neuronal excitability. The company employs advanced techniques in structural biology, medicinal chemistry, and electrophysiology to discover small molecule compounds that selectively modulate these protein complexes. By disrupting specific protein-protein interactions rather than directly blocking a receptor, the platform aims to achieve a refined therapeutic index and circuit-specific modulation within the brain, a significant challenge in treating disorders like epilepsy and chronic pain.

Clinical pipeline

The company's lead program, RAP-219, is an orally administered, brain-penetrant small molecule inhibitor of a specific receptor-associated protein complex, entering Phase I clinical trials for the potential treatment of focal epilepsy. A second disclosed program targets a different protein complex for neuropathic pain and is in the preclinical development stage. The pipeline strategy emphasizes high-unmet-need neurological conditions where current anticonvulsant or analgesic treatments are often limited by tolerability issues or insufficient efficacy. By focusing on the underlying pathophysiology of neuronal hyperexcitability through a novel mechanism, Rapport's candidates aim to provide more controlled modulation of disease-relevant neural circuits without the broad suppression of central nervous system function associated with many existing drugs.

Partnerships and collaborations

Rapport's primary strategic collaboration is with Johnson & Johnson Innovation, which co-led the company's Series A financing and provides both capital and strategic input. This relationship builds upon a long-standing scientific connection through founder David Bredt and provides Rapport with access to extensive drug development expertise in neuroscience. While currently operating with a focused internal research team, the company's platform has the potential to generate assets for broader central nervous system disorders, which may lead to future licensing agreements or research partnerships with larger pharmaceutical companies. The significant backing from Third Rock Ventures, a venture firm with a strong track record of building biotechnology companies, also represents a key collaborative relationship guiding corporate strategy and development.

Leadership and team

The company is led by Chief Executive Officer Abraham Ceesay, a seasoned biotechnology executive with prior leadership experience at Goldfinch Bio and Vertex Pharmaceuticals. Scientific founder David Bredt serves as the Chief Scientific Officer, guiding the research direction based on his decades of experience in synaptic pharmacology. The leadership team and board of directors include several veterans from successful neuroscience-focused biotechnology firms and pharmaceutical companies, combining deep expertise in neurology drug discovery, clinical development, and corporate strategy. This assembly of talent with proven experience in translating novel biological insights into medicines is considered a core strength for navigating the high-risk field of central nervous system therapeutic development.

Category:Biotechnology companies of the United States Category:Companies based in Boston Category:American companies established in 2022